Affiliated with a Castle Connolly Top Hospital
Who is Dr. Medeiros, Hematologist in Stanford, CA?
Dr. Bruno Medeiros, MD is a Hematologist, who primarily practices in Stanford, CA with 2 additional practice locations. He is board certified by the American Board of Internal Medicine. Dr. Medeiros graduated from Federal University of Parana and completed his residency at University of Colorado Health Science Center. Dr. Medeiros is fluent in English and Portuguese, and is currently seeing new patients. Dr. Medeiros’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Medeiros’s office at (650) 723-4000.
Where did Dr. Medeiros go to medical school and complete their residency?
Fellowship: Acute leukemia, Princess Margaret Hospital - University of Toronto | University of Colorado Health Science Center CO | Acute leukemia, Princess Margaret Hospital - University of Toronto
Residency: University of Colorado Health Science Center | University of Colorado Denver Affiliated Hospitals
Medical School: Federal University of Parana
Is Dr. Medeiros board certified in Hematologist?
Yes, Dr. Bruno Medeiros, MD is board certified by the American Board of Internal Medicine since 2006, American Board of Internal Medicine since 2005
What languages does Dr. Medeiros speak?
Dr. Medeiros and their clinical team can communicate with patients in the following languages:
English
Portuguese
What conditions does Dr. Medeiros treat?
As a Hematologist, Dr. Medeiros diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Medeiros. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Chronic Myeloid Leukemia
- Acute Lymphocytic Leukemia in Remission
- Acute Myeloid Leukemia in Remission
- Chronic Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Acute Promyelocytic Leukemia in Remission
- Acute Myeloid Leukemia in Relapse
- Acute Lymphoblastic Leukemia
- Chronic Myelogenous Leukemia Treatment (PDQ®)
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia Treatment (PDQ®)
- Acute promyelocytic leukemia
- CML
- Chronic myelogenous leukemia
- Philadelphia chromosome positive leukemia
- ALL Leukemia in Remission
- Acute Lymphoblastic Leukemia in Remission
- Childhood Leukemia in Remission
- AML Leukemia in Remission
- Acute Myeloblastic Leukemia in Remission
- Acute Myelogenous Leukemia in Remission
- CLL
- B-cell chronic lymphocytic leukemia
- Lymphocytic leukemia
- AML Leukemia
- Acute Myeloblastic Leukemia
- Acute Myelogenous Leukemia
- APL Leukemia in Remission
- Acute Myeloid Leukemia M3 in Remission
- Promyelocytic Leukemia in Remission
- AML Leukemia in Relapse
- Acute Myeloblastic Leukemia in Relapse
- Acute Myelogenous Leukemia in Relapse
- ALL
- Acute lymphocytic leukemia
- Lymphoblastic leukemia
ICD-10 Codes:
- C9210: Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
- C9101: Acute lymphoblastic leukemia, in remission
- C9201: Acute myeloblastic leukemia, in remission
- C9110: Chronic lymphocytic leukemia of B-cell type not having achieved remission
- C9200: Acute myeloblastic leukemia, not having achieved remission
- C9241: Acute promyelocytic leukemia, in remission
- C9202: Acute myeloblastic leukemia, in relapse
- C9100: Acute lymphoblastic leukemia not having achieved remission
Also known as:
- Multiple Myeloma
- Multiple Myeloma in Remission
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ)
- Active multiple myeloma
- Untreated multiple myeloma
- Plasma cell myeloma
- Plasma Cell Myeloma in Remission', 'Kahler's Disease in Remission
- Myeloma in Remission
ICD-10 Codes:
- C9000: Multiple myeloma not having achieved remission
- C9001: Multiple myeloma in remission
Also known as:
- Immune Thrombocytopenic Purpura
- Essential Thrombocythemia
- Platelet Disorder
- Immune thrombocytopenia
- Essential thrombocythemia
- Chronic Myeloproliferative Neoplasms Treatment (PDQ)
- ITP
- Idiopathic thrombocytopenic purpura
- Low platelet count
- ET
- Primary Thrombocythemia
- Hemorrhagic Thrombocythemia
ICD-10 Codes:
- D693: Immune thrombocytopenic purpura
- D473: Essential (hemorrhagic) thrombocythemia
Also known as:
- Monoclonal Gammopathy
- Blood Disorder
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ)
- MGUS
- Plasma Cell Disorder
- Gammopathy of Undetermined Significance
ICD-10 Codes:
- D472: Monoclonal gammopathy
Also known as:
- Low Neutrophil Count
- Blood Disorder
- Neutropenia
- Low white blood cell count
- Neutrophil deficiency
ICD-10 Codes:
- D709: Neutropenia, unspecified
Also known as:
- Polycythemia vera
- Bone Marrow Disease
- Chronic Myeloproliferative Neoplasms Treatment (PDQ)
- PV
- Primary polycythemia
- Erythremia
ICD-10 Codes:
- D45: Polycythemia vera
Also known as:
- Myelofibrosis
- Bone Marrow Disease
- Primary myelofibrosis
- Chronic idiopathic myelofibrosis
- Bone marrow scarring
ICD-10 Codes:
- D474: Osteomyelofibrosis
Also known as:
- Acute Heart Failure
- Heart Failure
- Sudden heart failure
- Acute congestive heart failure
- Sudden cardiac decompensation
ICD-10 Codes:
- I5021: Acute systolic (congestive) heart failure
Also known as:
- Idiopathic Hypereosinophilic Syndrome
- Eosinophilic Disorder
- IHES
- Hypereosinophilic syndrome of unknown cause
- Primary hypereosinophilic syndrome
ICD-10 Codes:
- D72110: Idiopathic hypereosinophilic syndrome [IHES]
Also known as:
- Hemochromatosis from Transfusions
- Hemochromatosis
- Transfusional Hemochromatosis
- Secondary Hemochromatosis
- Iron Overload from Blood Transfusions
ICD-10 Codes:
- E83111: Hemochromatosis due to repeated red blood cell transfusions
Which procedures does Dr. Medeiros perform as a Hematologist?
As a Hematologist, procedures performed by a Dr. Bruno Medeiros may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Medeiros' office.
Does Dr. Medeiros accept my insurance?
Dr. Medeiros accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Medeiros accept in Stanford, CA?
Dr. Medeiros in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Advantage
All Other Third Party
Blue Shield of California
Care N' Care
Central California Alliance for Health
CVS Health (formerly Aetna)
Medicaid
Medicare
Santa Clara Family Health Plan
UnitedHealthcare
View All Insurances
Where is Dr. Medeiros' office located?
Recognitions
Publications
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators
Proceedings of the tiol Academy of Sciences of the United States of Am, 2014
Unsuccessful diagnostic cytogenetic alysis is a poor prognostic feature in acute myeloid leukaemia
BRITISH JOURL OF HAEMATOLOGY, 2014
Sequential azacitidine plus lelidomide combition
Haematologica, 2013
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia
HAEMATOLOGICA-THE HEMATOLOGY JOURL, 2012
Safety, efficacy and biological predictors of response to sequential azacitidine and lelidomide for
LEUKEMIA, 2012
Tailored temozolomide therapy according to MGMT methylation status
AMERICAN JOURL OF HEMATOLOGY, 2012
Cytarabine Dose for Acute Myeloid Leukemia
NEW ENGLAND JOURL OF MEDICINE, 2011
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology .
Jourl of the tiol Comprehensive Cancer Network, 2014
Gemtuzumab ozogamicin in combition with vorinostat
HAEMATOLOGICA, 2014
Hematopoietic Stem Cell Transplantation for Hematologic Maligncies in Older Adults
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2014
Qualitative alysis of practicing oncologists' attitudes
Jourl of oncology practice / American Society of Clinical Oncology, 2013
A single-center experience of the tionwide daunorubicin shortage
Leukemia & lymphoma, 2013
Amrubicin, a Novel Investigatiol Anthracycline
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C.
A Phase I/II Study of Bortezomib
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., Med
Hemophagocytic lymphohistiocytosis in pregncy: a case report and review of treatment options
HEMATOLOGY, 2012
Waldenstrom's Macroglobulinemia
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Jourl of the tiol Comprehensive Cancer Network, 2012
Absolute lymphocyte count at day 28 independently predicts event-free
AMERICAN JOURL OF HEMATOLOGY, 2012
Novel agents in acute myeloid leukemia
INTERTIOL JOURL OF HEMATOLOGY, 2012
New treatment approaches for older adults with multiple myeloma
JOURL OF GERIATRIC ONCOLOGY, 2012
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post
HAEMATOLOGICA-THE HEMATOLOGY JOURL, 2012
Senior Adult Oncology
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2012
Phase I trial of a novel human monoclol antibody mAb216 in patients with relapsed or refractory B
HAEMATOLOGICA-THE HEMATOLOGY JOURL, 2012
Treatment advances have not improved the early death rate in acute promyelocytic leukemia
HAEMATOLOGICA-THE HEMATOLOGY JOURL, 2012
Multiple Myeloma
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2011
Acute myeloid leukaemia in the elderly: a review
BRITISH JOURL OF HAEMATOLOGY, 2011
Microfluidic purification and alysis of hematopoietic stem cells from bone marrow
LAB ON A CHIP, 2011
A Phase I Study of Sequential Azacitidine
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Go, 2010
Second-line mitoxantrone, etoposide
AMERICAN JOURL OF HEMATOLOGY, 2010
Plasma cell leukemia: concepts and magement.
Expert review of hematology, 2010
Plasma cell leukemia: concepts and magement
EXPERT REVIEW OF HEMATOLOGY, 2010
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with
AMERICAN JOURL OF HEMATOLOGY, 2010
PHASE 2 TRIAL OF VORINOSTAT
Walter, B., Medeiros, B., Nielsen-Stoeck, M., Harrington, E., Powell, , 2010
Multiple Myeloma
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2009
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia
AMERICAN JOURL OF HEMATOLOGY, 2009
NCCN clinical practice guidelines in oncology: multiple myeloma.
Jourl of the tiol Comprehensive Cancer Network, 2009
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
NEW ENGLAND JOURL OF MEDICINE, 2009
Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia
JOURL OF CLINICAL ONCOLOGY, 2009
Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia
JOURL OF CLINICAL ONCOLOGY, 2009
Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin
Cases jourl, 2009
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators
Proceedings of the National Academy of Sciences of the United States o, 2014
Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature
BRITISH JOURNAL OF HAEMATOLOGY, 2014
Sequential azacitidine plus lenalidomide combination
Haematologica, 2013
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012
Blood consult: monosomal karyotype acute myeloid leukemia
BLOOD, 2012
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide
LEUKEMIA, 2012
Impact of residual normal metaphases in core binding factor acute myeloid leukemia
CANCER, 2012
Unveiling the complexity of CK+ AML.
Blood, 2012
Tailored temozolomide therapy according to MGMT methylation status
AMERICAN JOURNAL OF HEMATOLOGY, 2012
Cytarabine Dose for Acute Myeloid Leukemia
NEW ENGLAND JOURNAL OF MEDICINE, 2011
Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia
BLOOD, 2010
Mcl-1 dependence predicts response to vorinostat
LEUKEMIA RESEARCH, 2014
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology .
Journal of the National Comprehensive Cancer Network, 2014
Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia.
Acta haematologica, 2014
Gemtuzumab ozogamicin in combination with vorinostat
HAEMATOLOGICA, 2014
Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014
Qualitative analysis of practicing oncologists' attitudes
Journal of oncology practice / American Society of Clinical Oncology, 2013
A single-center experience of the nationwide daunorubicin shortage
Leukemia & lymphoma, 2013
CD11b expression and MK+ AML: A sign of impending doom?
LEUKEMIA RESEARCH, 2013
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia
LEUKEMIA & LYMPHOMA, 2013
CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells
LEUKEMIA, 2012
Amrubicin, a Novel Investigational Anthracycline
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C.
Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine
Becker, P. S., Medeiros, B. C., Stein, A. S., Appelbaum, F. R., Scott,
A Phase I/II Study of Bortezomib
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., Med
Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options
HEMATOLOGY, 2012
Waldenstrom's Macroglobulinemia
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Journal of the National Comprehensive Cancer Network, 2012
Absolute lymphocyte count at day 28 independently predicts event-free
AMERICAN JOURNAL OF HEMATOLOGY, 2012
Novel agents in acute myeloid leukemia
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012
New treatment approaches for older adults with multiple myeloma
JOURNAL OF GERIATRIC ONCOLOGY, 2012
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012
Aggressive EBV-associated Lymphoproliferative Disorder
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012
Senior Adult Oncology
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012
It doesn't matter if you're black or white, does it?
LEUKEMIA RESEARCH, 2012
Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012
Treatment advances have not improved the early death rate in acute promyelocytic leukemia
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012
Phase 2 Trial of G-CSF Priming, Clofarabine
Becker, P. S., Medeiros, B. C., Appelbaum, F. R., Scott, B. L., Hendri, 2011
Multiple Myeloma
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011
Unfavorable-risk cytogenetics in acute myeloid leukemia
EXPERT REVIEW OF HEMATOLOGY, 2011
Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer
EXPERT OPINION ON THERAPEUTIC TARGETS, 2011
Acute myeloid leukaemia in the elderly: a review
BRITISH JOURNAL OF HAEMATOLOGY, 2011
Microfluidic purification and analysis of hematopoietic stem cells from bone marrow
LAB ON A CHIP, 2011
A Phase I Study of Sequential Azacitidine
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Go, 2010
Temozolomide In Acute Myeloid Leukemia
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., , 2010
Second-line mitoxantrone, etoposide
AMERICAN JOURNAL OF HEMATOLOGY, 2010
Plasma cell leukemia: concepts and management.
Expert review of hematology, 2010
Plasma cell leukemia: concepts and management
EXPERT REVIEW OF HEMATOLOGY, 2010
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with
AMERICAN JOURNAL OF HEMATOLOGY, 2010
PHASE 2 TRIAL OF VORINOSTAT
Walter, B., Medeiros, B., Nielsen-Stoeck, M., Harrington, E., Powell, , 2010
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
LEUKEMIA RESEARCH, 2010
Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, , 2009
Is Time of the Essence in Adult Acute Myeloid Leukemia
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., , 2009
Multiple Myeloma
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia
AMERICAN JOURNAL OF HEMATOLOGY, 2009
NCCN clinical practice guidelines in oncology: multiple myeloma.
Journal of the National Comprehensive Cancer Network, 2009
Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A.,
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
NEW ENGLAND JOURNAL OF MEDICINE, 2009
Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia
JOURNAL OF CLINICAL ONCOLOGY, 2009
Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia
JOURNAL OF CLINICAL ONCOLOGY, 2009
Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study
McGuire, A., Shier, L. R., Gotlib, J., Medeiros, B., Wong, K., Corless, 2009
Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin
Cases journal, 2009
What is Dr. Medeiros's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Medeiros's National Provider Identifier (NPI) number is 1760420657.
What common questions do patients ask about Dr. Medeiros?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Medeiros
What is Dr. Bruno Medeiros's specialty?
Dr. Medeiros is a Hematologist near Stanford, CA. An internist with advanced training specializing in disorders of the blood, spleen, and lymphatic system. This specialist manages conditions such as anemia, clotting disorders, sickle cell disease, hemophilia, leukemia, and lymphoma. Contact Dr. Medeiros to book an appointment today.
Is this Dr. Bruno Medeiros affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Medeiros is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Hematologist?
Explore Hematologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Bruno Medeiros accepting new patients in Stanford, CA?
Yes, Dr. Bruno Medeiros is accepting new patients at this time.
Does Dr. Bruno Medeiros offer online booking?
Please contact Dr. Medeiros's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Bruno Medeiros?
Please contact Dr. Medeiros's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Bruno Medeiros have?
Dr. Bruno Medeiros is certified by the American Board of Internal Medicine.
Other Hematologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patientsHematologist
Accepting patients